EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study

Mark T Reding, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Mark T Reding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM‐POWR study.

Methods

HEM‐POWR (NCT03932201) is a multinational, Phase 4, prospective observational study. The key objectives were the annualized bleeding rate (ABR) and adverse events.

Results

At data cutoff (July 8, 2024), the safety analysis set and full analysis set (FAS) included 370 and 270 patients, respectively. In the modified FAS (patients with ≥ 90 days of bleed data), the mean (standard deviation; SD) ABR for total bleeds was 2.8 (5.9) 12 months prior to damoctocog alfa pegol initiation with the previous FVIII product and 2.1 (4.8) during the observation period. Bleed protection with damoctocog alfa pegol was maintained across disease severity, age group, BMI group, dosing regimen, and patient inhibitor history. One patient died due to spinal cord ischemia unrelated to the study drug. One patient developed a transient low‐titer inhibitor, which resolved without clinical consequence.

Conclusions

This updated analysis further demonstrated the effectiveness, acceptable safety profile, and tolerability of damoctocog alfa pegol for previously treated patients with severe and nonsevere hemophilia A from adolescence to older age in a real‐world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AAdolescentAdultAgedChildChild, PreschoolFemaleHumansMaleMiddle AgedYoung AdultHemorrhageProspective StudiesSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

bleedingextended half‐lifehemophilia Ainhibitorsnonseverereal‐worldsafety

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
  • Thrombosis and Haemostasis Unit, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
  • Deming Department of Internal Medicine, Section of Hematology and Medical Oncology, Tulane School of Medicine, New Orleans, Louisiana, USA.
  • Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.

Förderung

  • Bayer

Zitieren

APA

Reding, M. T., Alvarez Román, M. T., Castaman, G., Janbain, M., Matsushita, T., Meijer, K., Schmidt, K., & Oldenburg, J. (2026). Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70026

Vancouver

Reding MT, Alvarez Román MT, Castaman G, Janbain M, Matsushita T, Meijer K, et al. Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70026

BibTeX
@article{Reding2026,
  author = {Reding, Mark T and Alvarez Román, María Teresa and Castaman, Giancarlo and Janbain, Maissaa and Matsushita, Tadashi and Meijer, Karina and Schmidt, Kathrin and Oldenburg, Johannes},
  title = {Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70026}
}
Kostenlos starten →